Suppr超能文献

基于 PEG-PLGA 的大孔颗粒用于肺部递送高水溶性药物,低分子量肝素。

PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin.

机构信息

Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Science Center, 1300 Coulter Drive, Amarillo, TX 79106, USA.

出版信息

J Control Release. 2012 Sep 10;162(2):310-20. doi: 10.1016/j.jconrel.2012.07.003. Epub 2012 Jul 16.

Abstract

This study was designed to evaluate the feasibility of PEG-PLGA copolymers as carriers for pulmonary delivery of a highly soluble drug. We attempt to address the limitations of low entrapment efficiencies and poor release profiles that are associated with the use of conventional PLGAs. We have used low molecular weight heparin (LMWH) as a model for highly soluble and ionizable drugs and a 3 × 3 full factorial design to prepare nine formulations. We considered polymer type and percent NaCl in external phase as two independent variables at three different levels; the levels for polymer type were PLGA, PEG-PLGA and PLGA-PEG-PLGA and that for percent NaCl were 0%, 5% and 8%. Formulations were characterized for various physical properties, respirability, drug release, and evaluated for in vivo absorption, alveolar uptake, and safety. Statistical analyses suggest that both polymer type and salt concentration influenced the morphology and micromeritic properties of the particles. Compared with PLGA, PEG-PLGA copolymers produced inherently larger porous particles with high drug entrapment and a greater extent of drug release. Moreover, addition of NaCl in the external phase maximized drug entrapment but minimized burst release and produced smaller and denser particles. Fluorescent PEG-PLGA particles showed reduced uptake by alveolar macrophages, and exhibited a uniform distribution in the lungs compared with PLGA particles. Further, ~85% of the particles were cleared off the lungs within 6 days. Intratracheally administered PEG-PLGA based optimized formulation exhibited a biological half-life of 18.64 h, which was ~4.5 times longer than plain LMWH. No cytotoxic effect was observed when bronchial epithelial cells were incubated with PEG-PLGA based formulations. Similarly, no increase in the injury markers was observed in the bronchoalveolar lavage fluids collected from rats treated with PEG-PLGA particles of LMWH. Overall, this study suggests that PEG-PLGA block copolymers have the potential to be developed as efficient and biocompatible carriers for pulmonary delivery of highly water-soluble drugs.

摘要

这项研究旨在评估 PEG-PLGA 共聚物作为高水溶性药物肺部给药载体的可行性。我们试图解决与使用传统 PLGA 相关的低包封效率和差的释放特性的限制。我们使用低分子量肝素 (LMWH) 作为高水溶性和可离子化药物的模型,并使用 3×3 完全析因设计制备了 9 种制剂。我们考虑了聚合物类型和外部相中的 NaCl 百分比作为两个独立变量,在三个不同水平上;聚合物类型的水平为 PLGA、PEG-PLGA 和 PLGA-PEG-PLGA,NaCl 百分比的水平为 0%、5%和 8%。制剂的各种物理性质、可呼吸性、药物释放进行了表征,并进行了体内吸收、肺泡摄取和安全性评价。统计分析表明,聚合物类型和盐浓度都影响了颗粒的形态和微粉特性。与 PLGA 相比,PEG-PLGA 共聚物产生了固有较大的多孔颗粒,具有较高的药物包封率和更大程度的药物释放。此外,在外部相中添加 NaCl 可最大限度地提高药物包封率,但最小化突释,并产生更小、更致密的颗粒。荧光 PEG-PLGA 颗粒显示出肺泡巨噬细胞摄取减少,与 PLGA 颗粒相比,在肺部中表现出均匀的分布。此外,约 85%的颗粒在 6 天内从肺部清除。气管内给予的基于 PEG-PLGA 的优化制剂表现出 18.64 小时的生物学半衰期,比普通 LMWH 长约 4.5 倍。当支气管上皮细胞与基于 PEG-PLGA 的制剂孵育时,未观察到细胞毒性作用。同样,在接受 LMWH 的 PEG-PLGA 颗粒治疗的大鼠的支气管肺泡灌洗液中也未观察到损伤标志物增加。总的来说,这项研究表明,PEG-PLGA 嵌段共聚物有可能被开发为高效且生物相容的高水溶性药物肺部给药载体。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验